why choose us

First received: December 20, 2022

Clinical Trial: Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Thyroid Eye Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Brief Summary: Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.

Read more